Active Biotech to present at UBS Global Life Sciences Conference.Business Editors/Health/Medical Writers LUND, Sweden--(BUSINESS WIRE)--Sept. 19, 2003 Active Biotech (ACTIb.ST) will be presenting the company at the 2003 UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference being held September 22-25, at the Plaza Hotel in New York. This annual conference is attended by approximately 3,000 investment professionals and pharmaceutical decision-makers. From Active Biotech will be present; Sven Andreasson CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Tomas Leanderson CSO and Hans Kolam CFO See Chief Financial Officer. . The presentation, scheduled to take place on Tuesday, September 23rd at 2:30 P.M. will cover the development opportunities for Active Biotech's oral multiple sclerosis product laquinimod (SAIK-MS) that recently successfully concluded a phase II study, as well as the ongoing clinical program for the cancer project TTS (Tumor Targeted Superantigens). Furthermore, an update of the company's phase I studies in prostate cancer and the planned Phase I study in Systemic Lupus Erythematosus Systemic Lupus Erythematosus Definition Systemic lupus erythematosus (also called lupus or SLE) is a disease where a person's immune system attacks and injures the body's own organs and tissues. Almost every system of the body can be affected by SLE. (SLE SLE systemic lupus erythematosus. SLE abbr. systemic lupus erythematosus Systemic lupus erythematosus (SLE) ) will be presented. For more details about Active Biotech and ongoing research project, please visit our web page www.activebiotech.com. Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK SAIK Sandvikens Aik ), as well as a novel concept for use in cancer immunotherapy (TTS). |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion